The SFCE group has just published in Pediatric Blood and Cancer the second part of their metronomic phase II trial entitled SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumors.
This trial is based on a pilot study initialy published in Oncotarget. Treatment consisted of an eight-week cycle of : oral celecoxib b.i.d., weekly vinblastine, oral cyclophosphamide for three weeks alternating with oral methotrexate for three weeks, with a two-week (…)